

Helicobacter Pylori vacA, cagA, iceA1, and iceA2 Genotypes in Gastrointestinal Diseases Patients from Mosul/Iraq

Muhammad Abdul-Ghani Muhammad¹, Basima Ahmed Abdullah², Anmar Ahmed Altaie³
^{1,2,3}Department of Biology, College of Science, University of Mosul, Mosul, Iraq



DOI : <https://doi.org/10.61796/jmgcb.v2i2.1152>



Sections Info

Article history:

Submitted: December 27, 2024
Final Revised: December 27, 2024
Accepted: December 28, 2024
Published: December 28, 2024

Keywords:

H. pylori
Virulence genes
Genotypes combination

ABSTRACT

Objective: *Helicobacter pylori* is a key cause of gastroduodenal disorders, with *cagA*-positive strains linked to gastric cancer primarily in Western populations. Other virulent genes may enhance the effects of *cagA* in disease development. This study sought to identify common *H. pylori* virulence genes in patients with gastrointestinal disorders. **Methods:** Biopsy specimens were collected from 100 patients. All DNA samples underwent PCR to confirm *H. pylori* infection, with positive samples further genotyped. Each PCR reaction used specific primers. **Results:** EGD findings indicated abnormalities in 89% of patients and normal results in 11%. The gene detection rate was 77%. Analysis of 77 samples showed virulence gene prevalence as 40.3% for *cagA*, 46.8% for *iceA1*, and 31.2% for *iceA2*, with 76.6% containing *vacA*. The *vacA* gene was the most common, except in normal findings, where *iceA1* was second, followed by *cagA* and *iceA2*. High *vacA* positivity was noted across various conditions, while *cagA* and *iceA2* were absent in some patient groups. A 100% positivity rate for *iceA1* was observed in patients with combined gastritis and gastric ulcers. The combination of *cagA*, *iceA1*, and *vacA* was observed in 20.8% of cases, while *vacA* and *iceA1* appeared in 18.2% and *vacA* and *iceA2* in 14.3%. Furthermore, the combination of *cagA*, *iceA2*, and *vacA* was found in 9.1% of cases. Conversely, the combined genotypes of *cagA* with *iceA1*, *iceA2*, and *vacA* were present at lower frequencies of 2.6%, 3.9%, and 3.9%, respectively. The individual occurrence of virulence factors varied, with *vacA* present in 10.4% of cases, *iceA1* in 5.2%, and *iceA2* in 3.9%. Additionally, *cagA*, *iceA1*, *iceA2*, and *vacA* genes were absent in 7.8% of cases. **Novelty:** This study reveals unique *H. pylori* virulence gene combinations and prevalence in Mosul, Iraq, offering regional-specific insights.

INTRODUCTION

Helicobacter pylori (*H. pylori*) is a spiral-shaped gram-negative bacterium that colonizes the gastric mucosa of more than half of the population worldwide. This bacterium is a leading cause of gastroduodenal diseases. Notably, *H. pylori* has been classified as a Group I carcinogen by the International Agency for Research on Cancer (IARC) since 1994 [1]. The pathogenesis of *H. pylori* infection is associated with their toxins, the most well-studied of which are the virulence factors cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA) [2], [3]. The *cagA* gene, located at the 3'-end of the *cag* pathogenicity island (*cagPAI*), encodes the CagA protein, which is prevalent in 60–70% of *H. pylori* worldwide [4], [5]. It is thought that *cagA*-positive *H. pylori* strains are a risk factor for gastric cancer (GC). However, this appears to be true only for *H. pylori* strains in Western countries, where the *cagA*-positivity rate for *H. pylori* is only about 40% [6]. At the same time, regardless of gastroduodenal disease, *H. pylori*

strains in East Asian countries exhibit extremely high rates of possessing the *cagA* gene, up to 90–95% [4], [7], [8]. Therefore, the *cagA* gene is not the only biological indicator for assessing the clinical outcome caused by *H. pylori* [9]. The *vacA* gene, which encodes the VacA protein, is found in all *H. pylori* strains. This vacuolating cytotoxin plays an important role in apoptosis and the pro-inflammatory response [7]. The diversity of *vacA* genotypes causes differences in cytotoxic activity between specific *H. pylori* strains [10], [11]. The signal region, which has two alleles (s1 and s2), the middle region, which has two alleles (m1 and m2), and the intermediate region, which has two alleles (i1 and i2), are the three main parts of the *vacA* gene [12], [13]. The *H. pylori* strains with the *vacA* s1m1 genotype exhibit the highest vacuolating activity, higher than the *vacA* s2m2 strains [10]. The toxicity of the *vacA* s1m2 strains is determined by the combination of alleles i1 or i2, with *vacA* s1i1m2 strains being vacuolating and *vacA* s1i2m2 strains being non-vacuolating [12].

Although *H. pylori* strains with both the *cagA* gene and vacuolating toxin-producing *vacA* genotypes are commonly found in patients with gastroduodenal diseases, a significant number of individuals infected with such *H. pylori* strains remain asymptomatic [14], [15]. Several other *H. pylori* virulence genes have been studied. Peek, in particular, discovered the *iceA* gene (induced by contact with epithelium gene A), whose transcription was induced by *H. pylori*'s adherence to the gastric epithelium. This gene has two major allelic variants, *iceA1* and *iceA2* [14]. A number of studies have considered the role of the *iceA* gene in conjunction with the *cagA* gene and the *vacA* gene in the pathogenesis of *H. pylori* [2], [16], [17]. The current study aimed to investigate the prevalence of *H. pylori cagA, vacA, and iceA* and the genotypes in gastrointestinal disease patients. The main objectives of this study were to identify the prevalence and genotypes combination of *H. pylori cagA, vacA, and iceA* genes among Mosul gastrointestinal disease patients.

RESEARCH METHOD

A. Patients and Clinical Specimens Patients and Clinical Specimens

The study was conducted between April 2023 and May 2024. Gastric biopsies were collected from one hundred patients who attended endoscopic units at Mosul hospitals. At least two gastric mucosa biopsy specimens were obtained from the corpus and antrum. Gastric mucosa biopsy specimens were kept at -20 °C in tubes containing PBS solution until performing the DNA extraction.

B. DNA Extraction

DNA was extracted from all 100 cases to confirm the *H. pylori* positivity and genotyping the *H. pylori cagA, vacA, and iceA* genes. First, the biopsy specimens were minced into small pieces using sterile scalpels, and then the DNA was extracted using QIAamp DNA Mini (Qiagen) according to the manufacturer's instructions. DNA concentration and purity were determined by nanodrop.

C. Conventional PCR

All DNA samples extracted from the gastric biopsies were submitted for conventional PCR using primers for 16S rRNA, ureC, and ureA genes to confirm *H. pylori* infection, the positive *H. pylori* for at least one of the three genes were submitted for genotypes using primers for vacA, iceA1, iceA2, and cagA. Each PCR reaction was performed by a single PCR using its specified primers pair except for housekeeping gene 16S rRNA was semi nested PCR was used. The sequences of primers and amplicon sizes are seen in Table 1.

Table 1. Set of primers used in PCR Technique used in the current study.

| Target gene | Primers sequence | Amplicon size(bp) | Annealing temperature °C | Reference |
|----------------------------|--|-------------------|--------------------------|-----------|
| 16S rRNA (Semi-nested PCR) | HPI: CTGGAGAGACTAAGCCCTCC Hp3: AGGATGAAGGTTTAAGGATT | 446 | 55 | |
| | HPI: CTGGAGAGACTAAGCCCTCC HP2: ATTACTGACGCTGATTGTGC | 110 | 62 | |
| ureC | glmM-F- AAGCTTTTAGGGGTGTTAGGGGT TT | 294 | 55 | (18) |
| | glmM-R-AAGCTTACTTTCTAAC ACTAACGC | | | |
| ureA | HPU1: GCCAATGGTAAATTAGTT HPU2: CTCCTTAATTGTTTTTAC | 411 | 45 | (18) |
| cagA | F: GATAACAGGCAAGCTTTTGAGG R: CTGCAAAAGATTGTTTGGCAGA | 349 | 52 | (10) |
| iceA1 | iceA1F:GTGTTTTTAACCAAAGTATC iceA1R:CTATAGCCASTYTCTTTGCA | 247 | 55 | |
| iceA2 | iceA2F:GTTGGGTATATCACAATTTA T iceA2R:TTRCCCTATTTTCTAGTAGGT | 229or329 | 55 | (2,16) |
| vacA | vacA-F F: - GCCGATATGCAAATGAGCCGC vacA-R R: - CAATCGTGTGGGTTCTGGAGC | 678 | 58 | (19) |

The reactions were carried in 25 µl volumes containing 12.5 GoTaq Green Master Mix 2X (Promega Corp., Madison, WI, USA), 1 µl for (10 pmol) each forward and reverse primer, and 3-5 µl (≤ 250 ng/µl) of DNA of the sample extracted DNA, made up to a total volume of 25 µl by adding nuclease-free water. The PCR cycling conditions are illustrated in Table 2. The amplification products were electrophoresed on 2% agarose gel.

Table 2. Optimum conditions were used for the PCR run for all set of primer used in this study to amplify targeted *H. pylori* genes.

| Partial amplified gene | Initial denaturation for 5 min. | Cycles NO. | Denaturation for 45 sec. | Annealing for 45 sec. | initial extension for 45 sec. | final extension for 5 min. |
|------------------------|---------------------------------|------------|--------------------------|--|-------------------------------|----------------------------|
| <i>16S rRNA</i> | 94 °C | 35 | 94 °C | 55 °C ¹ 62 °C ² | 72 °C | 72 °C |
| <i>ureC</i> | 94 °C | 35 | 94 °C | 55 °C | 72 °C | 72 °C |
| <i>ureA</i> | 94 °C | 35 | 94 °C | 45 °C | 72 °C | 72 °C |
| <i>cagA</i> | 94 °C | 35 | 94 °C | 55 °C | 72 °C | 72 °C |
| <i>vacA</i> | 94 °C | 35 | 94 °C | 58 °C | 72 °C | 72 °C |
| <i>iceA1</i> | 94 °C | 35 | 94 °C | 55 °C | 72 °C | 72 °C |
| <i>iceA2</i> | 94 °C | 35 | 94 °C | 55 °C | 72 °C | 72 °C |

1: annealing temperature for the first round of semi-nested PCR. 2: annealing temperature for the second round of semi-nested PCR.

RESULTS AND DISCUSSION

Results

Specialist physicians reported esopho-gastro-duodenal (EGD) findings. Gastrointestinal disorders of 100 patients were grouped according to EGD findings as having Gastritis (G), Hiatus Hernia (HH), Combined Gastritis and Lax Cardia (GLC), Combined Gastritis and Duodenitis (GD), Combined Gastritis and Hiatus Hernia (GHH), Combined Gastritis and Gastric Ulcers (GGU), and Normal endoscopic finding (N). In Figure 1 the findings from EGD revealed abnormal in (89%) and normal endoscopic in (11%) of the 100 patients.




Figure 1. Percentage of endoscopic findings in patients with gastrointestinal disorders.

The detection rate for at least one gene was 77%. Analysis of 77 samples for virulence genes prevalence showed a positive detection of 40.3% for *cagA*, 46.8% for *iceA1*, and 31.2% for *iceA2*. Furthermore, 76.6% of samples contained the *vacA* gene. Figure 2 illustrated the distribution of virulence genes among positive gastric biopsy samples for PCR with various endoscopic finding. The *vacA* gene was the predominant virulence gene detected in all endoscopic finding except for patients with normal endoscopic finding, whereas the *iceA1* gene was the second most common gene detected followed by *cagA* gene and finally the least dominant gene, the *iceA2* type. High positive frequency of *vacA* as detected 27/38(71.1%), 4/8(50%), 2/4(50%), 3/3(100%), 9/9(100%), 5/6(83.3%), 9/9(100%) in cases with gastritis, hiatus hernia, normal endoscopic finding, combined gastritis and lax cardia, combined gastritis and duodenitis, combined gastritis and hiatus hernia, combined gastritis and gastric ulcers respectively, while *cagA* and *iceA2* were not detected in patients with hiatus hernia and combined gastritis and gastric ulcers respectively. Also high positive frequency of *iceA1* gene was detected 9/9(100%) in patients with combined gastritis and gastric ulcers.




Figure 2. Distribution of virulence genes among positive gastric biopsy samples for PCR with various endoscopic finding.

The genotypes analysis of various *H. pylori* virulence genes revealed significant variations in the frequency of specific combined genotypes associated with virulence factors. The combined genotype of *cagA*, *iceA1*, and *vacA* was detected in 16 out of 77 cases (20.8%), in comparison, the combined genotype of *vacA* and *iceA1* was found in 14 cases (18.2%), while *vacA* and *iceA2* appeared in 11 cases (14.3%). Additionally, the combined genotype of *cagA*, *iceA2*, and *vacA* was detected in 7 cases (9.1%). In contrast, the lower frequencies of the combined genotypes involving *cagA* and *iceA1* (2.6%), *cagA* and *iceA2* (3.9%), and *cagA* and *vacA* (3.9%). The individual presence of the virulence factors also varies, with *vacA* detected alone in 8 out of 77 cases (10.4%), *iceA1* in 4 cases (5.2%), and *iceA2* in 3 cases (3.9%). Moreover, it is notable that virulence genes *cagA*, *iceA1*, *iceA2* and *vacA* were not detected in 6 out of 77 cases (7.8%) as depicted in Table 3.

Table 3. Distribution of various genotype combination of virulence genes among positive gastric biopsy samples for PCR according to endoscopic finding.

| Genotype Combination | Endoscopic Finding | | | | | | | Total No(%) |
|------------------------------------|--------------------|---------------------|---------------------------------|---|---|--|---|-------------|
| | Gastritis No(%) | Hiatus Hernia No(%) | Normal Endoscopic Finding No(%) | Combined Gastritis and Lax Cardia No(%) | Combined Gastritis and Duodinitis No(%) | Combined Gastritis and Hiatus Hernia No(%) | Combined Gastritis and Gastric Ulcers No(%) | |
| <i>cagA, iceA1</i> and <i>vacA</i> | 11(28.9) | 0(0) | 0(0) | 1(33.3) | 0(0) | 1(16.7) | 3(33.3) | 16(20.8) |
| <i>cagA, iceA2</i> and <i>vacA</i> | 3(7.9) | 0(0) | 2(50) | 0(0) | 2(22.2) | 0(0) | 0(0) | 7(9.1) |

| | | | | | | | | |
|-----------------------|---------|---------|--------|---------|---------|---------|---------|----------|
| <i>VacA and iceA1</i> | 3(7.9) | 1(12.5) | 0(0) | 1(33.3) | 3(33.3) | 0(0) | 6(66.7) | 14(18.2) |
| <i>vacA and iceA2</i> | 4(10.5) | 3(37.5) | 0(0) | 1(33.3) | 2(22.2) | 1(16.7) | 0(0) | 11(14.3) |
| <i>cagA and iceA1</i> | 1(2.6) | 0(0) | 1(25) | 0(0) | 0(0) | 0(0) | 0(0) | 2(2.6) |
| <i>cagA and iceA2</i> | 3(7.9) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 3(3.9) |
| <i>cagA and vacA</i> | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 3(50) | 0(0) | 3(3.9) |
| <i>vacA</i> | 6(15.9) | 0(0) | 0(0) | 0(0) | 2(22.2) | 0(0) | 0(0) | 8(10.4) |
| <i>iceA1</i> | 2(5.3) | 1(12.5) | 0(0) | 0(0) | 0(0) | 1(16.7) | 0(0) | 4(5.2) |
| <i>iceA2</i> | 2(5.3) | 0(0) | 1(25) | 0(0) | 0(0) | 0(0) | 0(0) | 3(3.9) |
| none | 3(7.9) | 3(37.5) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 6(7.8) |
| Total | 38(100) | 8(100) | 4(100) | 3(100) | 9(100) | 6(100) | 9(100) | 77(100) |

Discussion

The *cagA*, *vacA*, and *iceA* genotypes are essential for *H. pylori* toxicity. However, the role of these genes in the pathogenesis of gastroduodenal disease is controversial. The main causes are the geographical differences in the prevalence of *H. pylori* virulence genes and genotypes, as well as the synergic interaction between these genes. In this study, we performed DNA extraction from gastric mucosa biopsy specimens in order to investigate *H. pylori* virulence genes. This approach avoided the bacteria culture process, which requires time and labor. Regarding endoscopic findings, our findings aligns with findings from another study conducted in Iraq by [20] reported that (45.2%), (4.3%), (5.7%), (4.8%), (9.5%), (6.2%), (12.4%) and (11.9%) of 210 patients had gastritis, hiatus hernia, lax cardia, normal endoscopic findings, duodenitis, gastric ulcers, duodenal ulcers, and suspected gastric cancer respectively. The detection rates of *cagA* varied across studies, the prevalence ranges from (20.19%) in Burkina Faso [21] to (80%) in Brazil [22] and Vietnam [23]. In Iran, (72%) of *H. pylori*-positive samples contained the *cagA* gene [24], which higher than present study. Whereas in Iraq, a study reporting *cagA* in (39.21%) of specimens [25], moreover in Egypt a study conducted by [26] reported, the *CagA* gene was detected in (42.0%) of *H. pylori* +ve samples, which agree with present study. The *cagA* gene, consider as a marker of pathogenicity, the strains that carry the PAI are known to be more virulent than those lacking it [27]. The *iceA1* and *iceA2* genes are less frequently studied yet in a systematic review and meta-analysis of studies conducted in Iran reported a pooled prevalence of (36.2%) for *iceA1* and (26.2%) for *iceA2*. This suggests a higher prevalence of *iceA1* compared to *iceA2* in Iranian populations, which is consistent with the findings from individual studies in the region [28]. Another study in Iran found that (48%) of gastric biopsies were positive for *iceA1*, while (52%) contained *iceA2*(24). In Turkey, the prevalence rates of *iceA1* and *iceA2* were reported as (58%) and (26%), respectively [29]. A higher prevalence of *iceA1* compared to *iceA2* in this specific population agreed with present study. The *vacA* gene is one of the most prevalent

virulence factors of *H. pylori*. In Iraqi patients, the *vacA* gene was detected in (93.5%) of *H. pylori*-positive samples, making it the most common virulence gene identified [30]. In Iran, the *vacA* gene was present in (68%) of *H. pylori*-positive gastric biopsies, highlighting its widespread occurrence in different populations [24]. The absence of *vacA* in 18 biopsies samples in the current study could be a result of the genetic structure of the strains or exposure to adverse stomach conditions [31], [32]. The presence of *vacA*, along with other virulence factors like *cagA*, enhances the inflammatory response and tissue damage, leading to chronic gastritis and ulceration [33], [34].

CONCLUSION

Fundamental Finding : The study reveals a high prevalence and diversity of *Helicobacter pylori* virulence genes among individuals with gastrointestinal diseases in Mosul, Iraq. This underscores a significant association between the bacterium's genetic factors and the onset of these health issues, providing critical insights into the pathogenic mechanisms of *H. pylori* in the region. **Implication :** These findings highlight the urgent need for targeted public health interventions and diagnostic strategies in Mosul to address *H. pylori*-related diseases. Understanding the genetic diversity of virulence factors can aid in developing tailored treatment protocols and preventive measures to reduce the burden of gastrointestinal disorders. **Limitation :** The research is limited by its geographic focus on Mosul, which may not represent other regions, and by its reliance on a specific population sample. Broader studies incorporating diverse demographics and larger sample sizes are necessary to validate these findings and ensure their generalizability. **Future Research :** Future research should expand to include comparative analyses of *H. pylori* virulence genes in different regions and populations. Additionally, investigating the role of environmental, dietary, and genetic factors in modulating the bacterium's impact could enhance understanding and inform comprehensive disease management strategies.

REFERENCES

- [1] IARC *Helicobacter pylori* Working Group, "Helicobacter pylori eradication as a strategy for preventing gastric cancer," IARC Working Group Reports, vol. 8, 2014.
- [2] Y. Yamaoka, T. Kodama, O. Gutierrez, J. G. Kim, K. Kashima, and D. Y. Graham, "Relationship between *Helicobacter pylori* *iceA*, *cagA*, and *vacA* status and clinical outcome: Studies in four different countries," *J. Clin. Microbiol.*, vol. 37, no. 7, pp. 2274–2279, 1999.
- [3] I. Imoto et al., "Helicobacter pylori infection: Is there circulating vacuolating cytotoxin A or cytotoxin-associated gene A protein?," *Gut Pathog.*, vol. 14, no. 1, p. 43, 2022.
- [4] K. R. Jones, J. M. Whitmire, and D. S. Merrell, "A tale of two toxins: *Helicobacter pylori* *CagA* and *VacA* modulate host pathways that impact disease," *Front. Microbiol.*, vol. 1, p. 115, 2010.
- [5] M. Hatakeyama, "Helicobacter pylori *CagA* and gastric cancer: A paradigm for hit-and-run carcinogenesis," *Cell Host Microbe*, vol. 15, no. 3, pp. 306–316, 2014.

- [6] M. Hatakeyama, "Helicobacter pylori CagA—a bacterial intruder conspiring gastric carcinogenesis," *Int. J. Cancer*, vol. 119, no. 6, pp. 1217–1223, 2006.
- [7] Y. Yamaoka, "Mechanisms of disease: Helicobacter pylori virulence factors," *Nat. Rev. Gastroenterol. Hepatol.*, vol. 7, no. 11, pp. 629–641, 2010.
- [8] X. Zhu et al., "Rapid detection of cagA-positive Helicobacter pylori based on duplex recombinase aided amplification combined with lateral flow dipstick assay," *Diagn. Microbiol. Infect. Dis.*, vol. 103, no. 1, p. 115661, 2022.
- [9] S. Maeda et al., "Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan," *Gut*, vol. 42, no. 3, pp. 338–343, 1998.
- [10] J. C. Atherton et al., "Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori: Association of specific vacA types with cytotoxin production and peptic ulceration," *J. Biol. Chem.*, vol. 270, no. 30, pp. 17771–17777, 1995.
- [11] Z. Xue et al., "Geographic distribution of the cagA, vacA, iceA, oipA, and dupA genes of Helicobacter pylori strains isolated in China," *Gut Pathog.*, vol. 13, no. 1, p. 39, 2021.
- [12] J. L. Rhead et al., "A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer," *Gastroenterology*, vol. 133, no. 3, pp. 926–936, 2007.
- [13] R. M. Ferreira et al., "A novel method for genotyping the Helicobacter pylori vacA intermediate region directly in gastric biopsy specimens," *J. Clin. Microbiol.*, vol. 50, no. 12, pp. 3983–3989, 2012.
- [14] R. M. Peek Jr et al., "Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome," *Proc. Assoc. Am. Physicians*, vol. 110, no. 6, pp. 531–544, 1998.
- [15] P. Malfertheiner et al., "Helicobacter pylori infection," *Nat. Rev. Dis. Primers*, vol. 9, p. 19, 2023.
- [16] L. J. van Doorn et al., "Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori," *Gastroenterology*, vol. 115, no. 1, pp. 58–66, 1998.
- [17] M. T. Al-Ouqaili et al., "Study of vacuolating cytotoxin A (vacA) genotypes of ulcerogenic and non-ulcerogenic strains of Helicobacter pylori and its association with gastric disease," *Saudi J. Biol. Sci.*, vol. 30, no. 12, p. 103867, 2023.
- [18] J. J. Lu et al., "Comparison of five PCR methods for detection of Helicobacter pylori DNA in gastric tissues," *J. Clin. Microbiol.*, vol. 37, no. 3, pp. 772–774, 1999.
- [19] A. A. Almeahadi and F. Alsulaimany, "A DNA sequence analysis of Helicobacter pylori in Jeddah City, Western Saudi Arabia," *Int. J. Res. Pharm. Sci.*, vol. 11, no. 2, pp. 2758–2764, 2020.
- [20] K. D. Salman, A. N. Al-Thwaini, and B. A. Askar, "Evaluation of glmM gene in diagnosis of Helicobacter pylori with another invasive methods," *Iraqi J. Biotechnol.*, vol. 18, no. 3, pp. 16–25, 2019.
- [21] T. R. Compaore et al., "Helicobacter pylori virulence genes cagA, babA2, and vacA detection in dyspeptic patients from Burkina Faso," *Am. J. Mol. Biol.*, vol. 13, no. 3, pp. 141–155, 2023.
- [22] I. Brasil-Costa et al., "H. pylori infection and virulence factors cagA and vacA (s and m regions) in gastric adenocarcinoma from Pará State, Brazil," *Pathogens*, vol. 11, no. 4, p. 414, 2022.

- [23] N. N. T. Mai and T. H. T. Minh, "Prevalence of *cagA* gene and *vacA* genotypes of *Helicobacter pylori* among patients with gastroduodenal diseases," *J. Med. Pharm.*, vol. 12, no. 1, pp. 75–81.
- [24] E. Gholamhosseinzadeh et al., "Frequency of significant virulence genes in gastric biopsies of *Helicobacter pylori*-positive patients with gastritis," *AMB Express*, vol. 13, no. 1, p. 67, 2023.
- [25] E. A. Kalaf et al., "Multiplex PCR assay for detection of *Helicobacter pylori* isolated from Iraqi dyspeptic patients," *Iraqi J. Cancer Med. Genet.*, vol. 6, no. 1, pp. 49–54, 2013.
- [26] M. M. Alkherkhis et al., "Detection of cytotoxin-associated and vacuolating cytotoxin genotypes of *Helicobacter pylori* in patients with peptic inflammatory/ulcerative disorders," *Egyptian J. Hosp. Med.*, vol. 71, no. 6, pp. 3332–3342, 2018.
- [27] W. Fischer, "Assembly and molecular mode of action of the *Helicobacter pylori* Cag type IV secretion apparatus," *FEBS J.*, vol. 278, no. 8, pp. 1203–1212, 2011.
- [28] F. Kamarehei et al., "Prevalence of *Helicobacter pylori* virulence genes among Iranian infected patients: A systematic review and meta-analysis," *Rev. Res. Med. Microbiol.*, vol. 31, no. 4, pp. 191–200, 2020.
- [29] M. Akar et al., "Clinical relevance of virulence genes in *Helicobacter pylori* isolates recovered from adult dyspeptic patients in Turkey," *Indian J. Med. Microbiol.*, vol. 40, no. 2, pp. 258–262, 2022.
- [30] S. A. Al-Jumaili et al., "Prevalence of some *Helicobacter pylori* virulence genes such *vacA*, *oipA*, and *dupA* in Iraqi patients," *Res. J. Pharm. Technol.*, vol. 15, no. 10, pp. 4515–4518, 2022.
- [31] A. Idowu et al., "Detection of *Helicobacter pylori* and its virulence genes (*cagA*, *dupA*, and *vacA*) among patients with gastroduodenal diseases in Chris Hani Baragwanath Academic Hospital, South Africa," *BMC Gastroenterol.*, vol. 19, no. 73, pp. 1–10, 2019.
- [32] D. M. da Costa, E. dos Santos Pereira, and S. H. B. Rabenhorst, "What exists beyond *cagA* and *vacA*? *Helicobacter pylori* genes in gastric diseases," *World J. Gastroenterol.*, vol. 21, no. 37, pp. 10563–10572, 2015.
- [33] L. M. Nikulina, G. A. Solovyova, and K. L. Kvacheniuk, "Clinical manifestations and comorbid conditions in patients with chronic gastritis according to *Helicobacter pylori* CagA and VacA status," *Mod. Gastroenterol.*, vol. 5, no. 2, pp. 10–15, 2023.
- [34] Z. H. Alsaadi et al., "The association of *cagA*, *vacA*, *babA2*, *babB*, and *oipA* of *Helicobacter pylori* with risk of gastric carcinoma development," *J. Adv. Biomed. Sci.*, vol. 12, no. 4, pp. 406–411, 2022.

***Muhammad Abdul-Ghani Muhammad (Corresponding Author)**

Department of Biology, College of Science, University of Mosul, Mosul, Iraq
Email: mohasbio117@uomosul.edu.iq

Basima Ahmed Abdullah

Department of Biology, College of Science, University of Mosul, Mosul, Iraq
Email: basima.a@uomosul.edu.iq

Anmar Ahmed Altaie

Department of Biology, College of Science, University of Mosul, Mosul, Iraq
Email: anmaraltaee1978@uomosul.edu.iq
